Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 25, 2019 08:00 ET | Source: Wave Life Sciences

Wave Life Sciences to Present Suvodirsen Phase 1 Safety and Tolerability Data and Phase 2/3 Clinical Trial Design at the Muscular Dystrophy Association Clinical and Scientific Conference

CAMBRIDGE, Mass., March 25, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
March 06, 2019 08:00 ET | Source: Wave Life Sciences

Wave Life Sciences to Present at the Cowen 39th Annual Health Care Conference

CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
March 01, 2019 07:30 ET | Source: Wave Life Sciences

Wave Life Sciences Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass., March 01, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...
January 24, 2019 08:48 ET | Source: Wave Life Sciences

Wave Life Sciences Prices $150 Million Public Offering of Ordinary Shares

CAMBRIDGE, Mass., Jan. 24, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious,...
January 23, 2019 16:23 ET | Source: Wave Life Sciences

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares

CAMBRIDGE, Mass., Jan. 23, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a genetic medicines company focused on delivering transformational therapies for patients with serious,...
January 03, 2019 08:00 ET | Source: Wave Life Sciences

Wave Life Sciences Duchenne Muscular Dystrophy Clinical Trial Selected for FDA Complex Innovative Trial Designs Pilot Program

Suvodirsen (WVE-210201) Phase 2/3 trial chosen in inaugural round of pilot program FDA pilot program is a 21st Century Cures Act initiative CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) --...
December 06, 2018 07:30 ET | Source: Wave Life Sciences

Wave Life Sciences Announces Positive Phase 1 Results for WVE-210201 in Duchenne Muscular Dystrophy (DMD)

WVE-210201 safety and tolerability profile supports Phase 2/3 clinical trial initiation in boys with DMD amenable to exon 51 skipping Delivery of interim efficacy data from ongoing open-label...
November 09, 2018 07:30 ET | Source: Wave Life Sciences

Wave Life Sciences Reports Third Quarter 2018 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious,...
November 08, 2018 08:59 ET | Source: Wave Life Sciences

Wave Life Sciences to Present at the Jefferies 2018 London Healthcare Conference

CAMBRIDGE, Mass., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering transformational therapies for patients with serious,...
October 09, 2018 07:30 ET | Source: Wave Life Sciences

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290 Initial development candidate expected in H2 2019 CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE...